CNS Drugs

, Volume 20, Issue 1, pp 51–66 | Cite as

Prescription Privileges for Psychologists

A Comprehensive Review and Critical Analysis of Current Issues and Controversies
Review Article

Abstract

The debate over whether clinical psychologists should be granted the right to prescribe psychoactive medications has received considerable attention over the past 2 decades in North America and, more recently, in the UK. Proponents of granting prescription privileges to clinical psychologists argue that mental healthcare services are in crisis and that the mental health needs of society are not being met. They attribute this crisis primarily to the inappropriate prescribing practices of general practitioners and a persistent shortage of psychiatrists. It is believed that, as they would increase the scope of the practice of psychology, prescription privileges for psychologists would enhance mental health services by increasing public access to qualified professionals who are able to prescribe. The profession of psychology remains divided on the issue, and opponents have been equally outspoken in their arguments.

The purpose of the present article is to place the pursuit of prescription privileges for psychologists in context by discussing the historical antecedents and major forces driving the debate. The major arguments put forth for and against prescription privileges for psychologists are presented, followed by a critical analysis of the validity and coherence of those arguments. Through this analysis, the following question is addressed. Is there currently sufficient empirical support for the desirability, feasibility, safety and cost effectiveness of granting prescription privileges to psychologists?

Although proponents of granting prescription privileges to psychologists present several compelling arguments in favour of this practice, there remains a consistent lack of empirical evidence for the desirability, feasibility, safety and cost effectiveness of this proposal. More research is needed before we can conclude that prescription privileges for psychologists are a safe and logical solution to the problems facing the mental healthcare system.

Keywords

Mental Health Professional American Psychological Association Clinical Psychologist Mental Healthcare Psychoactive Medication 

Notes

Acknowledgements

The authors acknowledge the support of their work by the Canadian Institutes of Health Research (CIHR) and the Auger Research Foundation at Hôpital du Sacré-Coeur de Montréal. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Norfleet MA. Responding to society’s needs: prescription privileges for psychologists. J Clin Psychol 2002; 58(6): 599–610PubMedCrossRefGoogle Scholar
  2. 2.
    DeLeon PH, Fox RE, Graham SR. Prescription privileges: psychology’s next frontier. Am Psychol 1991 Apr; 46(4): 384–93PubMedCrossRefGoogle Scholar
  3. 3.
    DeLeon PH, Wiggins Jr JG. Prescription privileges for psychologists. Am Psychol 1996; 51(3): 225–9PubMedCrossRefGoogle Scholar
  4. 4.
    DeLeon PH, Sammons MT, Sexton JL. Focusing on society’s real needs: responsibility and prescription privileges? Am Psychol 1995; 50: 1022–32CrossRefGoogle Scholar
  5. 5.
    Scope of practice: psychologist prescribing legislation. American Psychiatric Association. 2003 May [online]. Available from URL: http://www.psych.org/advocacy_policy/leg_issues/prescribing_issues/rxfactsheetam43003.pdf [Accessed 2005 Apr 22]
  6. 6.
    McFall RM. Training for prescriptions vs. prescriptions for training: where are we now? Where should we be? How do we get there? J Clin Psychol 2002; 58(6): 659–76PubMedCrossRefGoogle Scholar
  7. 7.
    Albee GW. Just say no to psychotropic drugs! J Clin Psychol 2002; 58: 635–48Google Scholar
  8. 8.
    Hayes SC, Walser RD, Bach P. Prescription privileges for psychologists: constituencies and conflicts. J Clin Psychol 2002; 58(6): 697–708PubMedCrossRefGoogle Scholar
  9. 9.
    Hayes SC, Blackledge JT. Creating an alternative to prescription privileges in the era of managed care. In: Hayes SC, Heiby EM, editors. Prescription privileges for psychologists: a critical appraisal. Reno (NV): Context Press, 1998: 261–78Google Scholar
  10. 10.
    Hayes SC, Heiby EM. Psychology’s drug problem: do we need a fix or should we just say no? Am Psychol 1996; 51: 198–206PubMedCrossRefGoogle Scholar
  11. 11.
    Hayes SC, Heiby EM, editors. Prescription privileges for psychologists: a critical appraisal. Reno (NV): Context Press, 1998Google Scholar
  12. 12.
    DeNelsky GY. Prescription privileges for psychologists: the case against. Prof Psychol Res Pr 1991; 22(3): 188–93CrossRefGoogle Scholar
  13. 13.
    McReynolds P. Lightner Witmer: a centennial tribute. Am Psychol 1996; 51: 237–40CrossRefGoogle Scholar
  14. 14.
    Reisman JM. A history of clinical psychology. 2nd ed. New York: Hemisphere, 1991Google Scholar
  15. 15.
    Committee on Training in Clinical Psychology. Recommended graduate training program in clinical psychology. Am Psychol 1947; 2: 539–58CrossRefGoogle Scholar
  16. 16.
    Miller JG. Clinical psychology in the Veterans Administration. Am Psychol 1946; 1: 181–9PubMedCrossRefGoogle Scholar
  17. 17.
    Humphreys K. Clinical psychologists as psychotherapists: history, future, and alternatives. Am Psychol 1996; 51: 190–7PubMedCrossRefGoogle Scholar
  18. 18.
    Gilgen AR. American psychology since World War II: a profile of the discipline. Westport (CT): Greenwood Press, 1982Google Scholar
  19. 19.
    Rosenbaum JF. Attitudes toward benzodiazepines over the years. J Clin Psychiatry 2005; 66 Suppl. 2: 4–8Google Scholar
  20. 20.
    Alford GS. Pharmacotherpay. In: Hersen M, Kazdin AE, Bellack AS, editors. The clinical psychology handbook. New York: Pergamon Press, 1983: 631–56Google Scholar
  21. 21.
    Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995Google Scholar
  22. 22.
    Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2003; (2): CD004186Google Scholar
  23. 23.
    MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326: 1014PubMedCrossRefGoogle Scholar
  24. 24.
    Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005 Jan; 10(1): 49–56PubMedGoogle Scholar
  25. 25.
    Ham P, Waters DB, Oliver MN. Treatment of panic disorder. Am Fam Physician 2005 Feb 15; 71(4): 733–9PubMedGoogle Scholar
  26. 26.
    Katzman M. Venlafaxine in the treatment of anxiety disorders. Med Sci Monit 2004 Jul; 10 (7): CR288-93. Epub 2004 Jun 29Google Scholar
  27. 27.
    Lapid MI, Rummans TA. Evaluation and management of geriatric depression in primary care. Mayo Clin Proc 2003; 78: 1423–9PubMedCrossRefGoogle Scholar
  28. 28.
    Manning JS. Difficult-to-treat depressions: a primary care perspective. J Clin Psychiatry 2003; 64 Suppl. 1: 24–31Google Scholar
  29. 29.
    Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ 2002 Nov; 167(11): 1253–60PubMedGoogle Scholar
  30. 30.
    Hansen DG, Vach W, Rosholm JU, et al. Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Fam Pract 2004 Dec; 21(6): 623–9PubMedCrossRefGoogle Scholar
  31. 31.
    Zimmerman MA, Wienckowski LA. Revisiting health and mental health linkages: a policy whose time has come…again. J Public Health Policy 1991; 12: 510–24PubMedCrossRefGoogle Scholar
  32. 32.
    Christiansen A, Jacobson NS. Who (or what) can do psychotherapy: the status and challenge of nonprofessional therapies. Psychol Sci 1994; 5: 8–14CrossRefGoogle Scholar
  33. 33.
    Dawes RM. House of cards. New York: Free Press, 1994Google Scholar
  34. 34.
    Cummings NA. Impact of managed care on employment and training: a primer for survival. Prof Psychol Res Pr 1995; 26: 10–5CrossRefGoogle Scholar
  35. 35.
    Chiefetz DI, Salloway JC. Patterns of mental health services provided by HMOs. Am Psychol 1984; 39: 495–502CrossRefGoogle Scholar
  36. 36.
    Egli D. Psychopharmacology in independent practice: prescription privileges [letter]. The Independent Practitioner 1994b; 14: 218Google Scholar
  37. 37.
    Drug sales globally continue to increase. IMS Health; 2002 Aug [online]. Available from URL: http://www.chiropractichelps/com/drgsalesgctoinc.html [Accessed 2005 May 7]
  38. 38.
    Brentar J, McNamara JR. Prescription privileges for psychologists: the next step in its evolution as a profession. Prof Psychol Res Pr 1991; 22: 194–5CrossRefGoogle Scholar
  39. 39.
    Health Canada. The regulation of prescription drugs: roles and responsibilities. Health Canada Online; 2004 May [online]. Available from URL: http://www.hc-sc.gc.ca/english/media/releases/2004/internet_pharmacybk1.htm [Accessed 2005 Apr 22]
  40. 40.
    National Health Service Modernisation Agency, Department of Health. Medicines matters: a guide to current mechanisms for the prescribing, supply and administration of medicines [online]. Available from URL: http://www.content.modern.nhs.uk/cmsWISE/Workforce+Themes/Using_Task_Skills_Effectively/workingsafely/prescribing/prescribing.htm [Accessed 2005 Apr 22]
  41. 41.
    Dozois DJ, Dobson KS. Should Canadian psychologists follow the APA trend and seek prescription privileges? A reexamination of the (r)evolution. Can J Psychol 1995 Nov; 36(4): 288–304CrossRefGoogle Scholar
  42. 42.
    Lavoie KL, Fleet RP. Should psychologists be granted prescription privileges? A review of the prescription privilege debate for psychiatrists. Can J Psychiatry 2002 Jun; 47(5): 443–9PubMedGoogle Scholar
  43. 43.
    Sussman S. Re: should psychologists be granted prescription privileges? A review of the prescription privilege debate for psychiatrists [letter]. Can J Psychiatry 2003 Aug; 48(7): 497–8PubMedGoogle Scholar
  44. 44.
    Williams-Nickelson C. Prescription privileges fact sheet: what students should know about the APA’s pursuit of prescription privileges for psychologists (RxP). APA Practice Directorate, APA Monitor 2002Google Scholar
  45. 45.
    Sammons MT, Olmedo E. The prescription privileges agenda in 1997: forward progress, future goals. Prof Psychol Res Pr 1997 Dec; 28(6): 507–8CrossRefGoogle Scholar
  46. 46.
    Americal Psychological Association —Practice Directorate. New Mexico governor signs landmark law on prescription privileges for psychologists. APA Practice Directorate. In: The APA/Division Dialogue 2002 May/Jun [online]. Available from URL: http://www.apa.org/about/division/practicemay02.html [Accessed 2005 Apr 11]
  47. 47.
    Sammons MT, Brown AB. The department of defense psychopharmacology demonstration project: an evolving program for postdoctoral education in psychology. Prof Psychol Res Pr 1997 Apr; 28(2): 107–12CrossRefGoogle Scholar
  48. 48.
    Murray B. A brief history of RxP. APA Monitor 2003; 34: 66Google Scholar
  49. 49.
    Daw Holloway J. Psychologists persevere in the states. APA Monitor 2003; 34: 28Google Scholar
  50. 50.
    Holloway J. New Mexico becomes first state to gain Rx privileges. APA Monitor 2002; 33: 1Google Scholar
  51. 51.
    Daw Holloway J. Louisiana grants psychologists prescriptive authority. APA Monitor 2004; 35: 1Google Scholar
  52. 52.
    Dittman M. Psychology’s first prescribers. APA Monitor 2003; 34: 36Google Scholar
  53. 53.
    Daw Holloway J. Steady and strong progress in the push for Rx privileges. APA Monitor 2002; 33: 1Google Scholar
  54. 54.
    Ax RK, Forbes MR, Thompson D. Prescription privileges for psychologists: a survey of predoctoral interns and directors of training. Prof Psychol Res Pr 1997 Dec; 28(6): 509–14CrossRefGoogle Scholar
  55. 55.
    Cullen EA, Newman R. In pursuit of prescription privileges. Prof Psychol Res Prac 1997 Apr; 28(2): 101–6CrossRefGoogle Scholar
  56. 56.
    Fox RE. Prescription privileges: their implications for the practice of psychology. Psychotherapy 1988; 25: 501–7CrossRefGoogle Scholar
  57. 57.
    Fisher K, Buie J. Prescription privilege points, counterpoints ebated at convention. APA Monitor 1987; 11: 6–7Google Scholar
  58. 58.
    Wiggins JG. The care for prescription privileges for psychologists. Psychotherapy in Private Practice 1992; 11: 3–8Google Scholar
  59. 59.
    Welsh RS. To medicate or not to medicate: let us be honest about why we should [letter]. Am Psychol 1992; 47: 1678PubMedCrossRefGoogle Scholar
  60. 60.
    American Psychiatric Association. Scope of practice: psychologist prescribing legislation American Psychiatric Association 2003 May [online]. Available from URL: http://www.psych.org/advocacy_policy/leg_issues/prescribing_issues/rxfactsheetam43003.pdf [Accessed 2005 Apr 6]
  61. 61.
    Hausman K. Nurse practitioners in NY allowed to diagnose, prescribe. Psychiatr News 1988; 9: 11–2Google Scholar
  62. 62.
    Lazarus JA. Implications for medication errors and patient safety. Psychiatr Serv 2004 Dec; 55(12): 1423–4Google Scholar
  63. 63.
    Dobson KS, Dozois DJA. Professional psychology and the prescription debate: still not ready to go to the altar. Can J Psychol 2001 May; 42(2): 131–5CrossRefGoogle Scholar
  64. 64.
    Plante TG, Boccaccini M, Andersen E. Attitudes concerning professional issues impacting psychotherapy practice among members of the American Board of Professional Psychology. Psychotherapy: Theory, Research, and Practice 1998; 35(1): 34–42CrossRefGoogle Scholar
  65. 65.
    Narrow WE. One-year prevalence of mental disorders, excluding substance use disorders, in the US: NIMH ECA prospective data. Population estimates based on US Census estimated residential population age 18 and over on July 1, 1998. (Data on file)Google Scholar
  66. 66.
    US Department of Health and Human Services. Mental health: a report of the surgeon general. Rockville (MD): US Department of Health and Human Services, 1999Google Scholar
  67. 67.
    US Department of Health and Human Services. The President’s new freedom commission on mental health: achieving the promise: transforming mental health care in America. Rockville (MD): US Department of Health and Human Services, 2003Google Scholar
  68. 68.
    American Psychiatric Association. Resident matching numbers appear to have plateaued. Psychiatr News, 1998 Apr 3Google Scholar
  69. 69.
    Marra T. Should clinical psychologists have prescription privileges in California [letter]? Psychiatric Times 1994 Feb 20; 3: 20Google Scholar
  70. 70.
    Fulgieri MD. Prescription privileges for psychologists: an examination of the development of consumer attitudes [dissertation]. Dissertation Abstract International: Section B: The Sciences & Engineering, 2000 Aug; 62(2-B): 1080Google Scholar
  71. 71.
    Staff. Nurses, other professional want bigger share. Bigger Roles 1993 Apr; 3, 7, 8, 23Google Scholar
  72. 72.
    DeLeon PH. Prescription privileges: evolutions within the APA governance. National Register for Archives and Manuscripts 1993; 1-10Google Scholar
  73. 73.
    Pimental PA, Stout CE, Hoover MS, et al. Changing psychologists’ opinions about prescriptive authority: a little information goes a long way. Prof Psychol Res Pr 1997; 28: 123–7CrossRefGoogle Scholar
  74. 74.
    McGrath E, Keita GP, Strickland BR, et al., editors. Women and depression: risk factors and treatment issues: final report of APA national task force on women and depression. Washington, DC: American Psychological Association, 1990Google Scholar
  75. 75.
    Moran M, Thompson T, Nies A. Sleep disorders in the elderly. Am J Psychiatry 1988; 145: 1369–78PubMedGoogle Scholar
  76. 76.
    De Las Cuevas C, Sanz EJ. Controversial issues associated with the prescription of benzodiazepines by general practitioners and psychiatrists. Med Sci Monit 2004; 10(7): 288–93Google Scholar
  77. 77.
    Bell PF, Digman Jr RH, McKenna JP. Should psychologists obtain prescribing privileges? A survey of family physicians. Prof Psychol Res Pr 1995; 26(4): 371–6CrossRefGoogle Scholar
  78. 78.
    McGill Faculty of Medicine [online]. Available from URL: http://www.medicine.mcgill.ca/ [Accessed 2005 Apr 22]
  79. 79.
    University of Toronto Faculty of Medicine [online]. Available from URL: http://www.facmed.utoronto.ca/scripts/index_.asp [Accessed 2005 Apr 22]
  80. 80.
    GPs get new anti-depressant rules. BBC News UK edition; 2004 Dec [online]. Available from URL: http://news.bbc.co.uk/1/hi/health/4071145.stm [Accessed 2004 Dec 6]
  81. 81.
    Sweet JJ, Rozensky RH, Tovian SM, editors. Handbook of clinical psychology in medical settings. New York: Plenum, 1992Google Scholar
  82. 82.
    Smith BS. Attitudes toward prescribing privileges among clinical graduate students. Terre Haute (IN): Indiana State University, 1992. (Data on file)Google Scholar
  83. 83.
    Walters GD. A meta-analysis of opinion data on the prescription privilege debate. Can Psychol 2001 May; 42(2): 119–25CrossRefGoogle Scholar
  84. 84.
    deMayo RA. Academic interests and experiences of doctoral students in clinical psychology: implications for prescription privilege training. Prof Psychol Res Pr 2002; 33(5): 499–501CrossRefGoogle Scholar
  85. 85.
    St-Pierre ES, Melnyk WT. The prescription privilege debate in Canada: the voices of today’s and tomorrow’s psychologists. Can J Psychol 2004; 45(4): 284–92CrossRefGoogle Scholar
  86. 86.
    Kinderman P. Prescription rights: are we ready for change? [letter]. Psychologist 2003 Jun; 16(6): 287–8Google Scholar
  87. 87.
    Orford J. Prescription rights peer commentary: don’t go there [letter]. Psychologist 2003 Apr; 16(4): 189Google Scholar
  88. 88.
    Johnston L. Prescription rights: peer commentary: back to basics [letter]. Psychologist 2003 Apr; 16(4): 186Google Scholar
  89. 89.
    Gutierrez PM, Silk KR. Precription privileges for psychologists: a review of the psychological literature. Prof Psychol Res Pr 1998; 29: 213–22CrossRefGoogle Scholar
  90. 90.
    Wagner MK. The high cost of prescription privileges. J Clin Psychol 2002; 58(6): 677–80PubMedCrossRefGoogle Scholar
  91. 91.
    Weiner J. Editorial. Psychiatric News 1995; 30: 5Google Scholar
  92. 92.
    Yates DF. Should psychologists have prescribing authority? A psychologist’s perspective. Psychiatr Serv 2004 Dec; 55(12): 1420–1PubMedCrossRefGoogle Scholar
  93. 93.
    DoD Prescribing Psychologists: external analysis, monitoring, and evaluation of the program and its participants. Nashville (TN): American College of Neuropsychopharmacology, 1998Google Scholar
  94. 94.
    Prescribing Psychologists: DoD demonstration: participants perform well but have little effect on readiness or costs. Pub GAO/HEHS-99-98. Washington, DC: US General Accounting Office, 1999Google Scholar
  95. 95.
    Buie J. Practice priorities: Medicare amendments, hospital privileges, HMO reforms, prescription privileges. APA Monitor 1988; 1: 14–5Google Scholar
  96. 96.
    Peterson DR. Making psychology indispensable. Appl Prev Psychol 1996; 5: 1–8CrossRefGoogle Scholar
  97. 97.
    Caccavale J. Opposition to prescriptive authority: is this a case of the tail wagging the dog? J Clin Psychol 2002; 58(6): 623–33PubMedCrossRefGoogle Scholar
  98. 98.
    Kaplan HI, Sadock BJ, editors. Synopsis of psychiatry. 8th ed. Maryland: Williams and Wilkens, 1998Google Scholar
  99. 99.
    Dittmann M. State Leadership Conference. Prescriptive authority: DoD-trained psychologists spoke about how prescribing has changed clinical practice. APA Monitor 2004 May; 35: 5Google Scholar
  100. 100.
    Antonuccio DO, Thomas M, Danton WG. A cost-effectiveness model: is pharmacotherapy really less expensive than psychotherapy for depression. In: Hayes SC, Heiby EM, editors. Prescription privileges for psychologists: a critical appraisal. Reno (NV): Context Press, 1998Google Scholar
  101. 101.
    DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005 Apr; 62(4): 409–16PubMedCrossRefGoogle Scholar
  102. 102.
    Antonuccio DO, Danton WG, DeNelsky GY, et al. Raising questions about antidepressants. Psychother Psychosom 1999; 68: 3–14PubMedCrossRefGoogle Scholar
  103. 103.
    Antonuccio DO, Danton WG, DeNelsky GY. Psychotherapy versus medication for depression: challenging the conventional wisdom with data. Prof Psychol Res Pr 1995; 26(6): 574–85CrossRefGoogle Scholar
  104. 104.
    DeRubeis RD, Crits-Christoph P. Empirically supported individual and group psychological treatments for adult mental disorders. Consult Clin Psychol 1998 Feb; 66(1): 37–52CrossRefGoogle Scholar
  105. 105.
    Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005 Apr; 62(4): 417–22PubMedCrossRefGoogle Scholar
  106. 106.
    Evans MS, Hollon SD, DeRubeis RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992 Oct; 49(10): 802–8PubMedCrossRefGoogle Scholar
  107. 107.
    Anderson BL. Biobehavioral outcomes following psychological interventions for cancer patients. J Consult Clin Psychol 2002; 70(3): 590–610CrossRefGoogle Scholar
  108. 108.
    Fawzy FI, Kemeney ME, Fawzy NW, et al. A structured psychiatric intervention for cancer patients. Arch Gen Psychiatry 1990; 47: 729–35PubMedCrossRefGoogle Scholar
  109. 109.
    Halley FM. Self-regulation of the immune system through biobehavioural strategies. Biofeedback Self Regul 1999; 16: 55–73CrossRefGoogle Scholar
  110. 110.
    Berkowitz RI, Wadden T, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003 Apr 9; 289(14): 1805–12PubMedCrossRefGoogle Scholar
  111. 111.
    Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996; 156: 745–52PubMedCrossRefGoogle Scholar
  112. 112.
    Guiry E, Conroy RM, Hickey N, et al. Psychological response to an acute coronary event and its effect on subsequent rehabilitation and lifestyle change. Clin Cardiol 1987; 10: 256–60PubMedCrossRefGoogle Scholar
  113. 113.
    Kelly JA, Kalichman SC. Behavioral research in HIV/AIDS primary and secondary prevention: recent advances and future directions. J Consult Clin Psychol 2002; 70(3): 626–39PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Division of Chest Medicine, Research CenterHôpital du Sacré-Coeur de MontrealMontrealCanada
  2. 2.Department of PsychologyUniversity of Quebec at Montreal (UQAM)MontrealCanada
  3. 3.Department of PsychologyMcGill UniversityMontrealCanada

Personalised recommendations